secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001564590-22-019084
Event type: earnings
Sentiment:  neutral
Materiality: 0.45
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Q1 net loss $29.5M ($0.63/sh); cash $266.2M funds into 2H2024; on track for data readouts in 2H2022
--------------------------------------------------------------------------------

- Net loss $29.5M ($0.63/sh) vs $21.3M ($0.47) YoY; R&D expense $22.8M ($16.5M) on increased clinical activity.
- Cash & equivalents $266.2M as of March 31, 2022, expected to fund operations into second half 2024.
- PRMT5 program (PRT811) expansion cohort data analysis ongoing; next steps decision in 2H2022.
- MCL1 inhibitor PRT1419 IV formulation prioritized; combination cohorts expected by mid-2022.
- Jane Huang appointed President and CMO effective April 4, 2022; previously CMO Hematology at BeiGene.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/0001564590-22-019084-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000156459022019084/prld-8k_20220510.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019084

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer